Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Published Date: 11 Sep 2024

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

2.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

3.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

4.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

5.

Cancer patients want financial screening early in care, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot